Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)

Leuk Lymphoma. 2021 Oct;62(10):2539-2542. doi: 10.1080/10428194.2021.1919668. Epub 2021 May 11.
No abstract available

Publication types

  • Letter
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cytarabine
  • Daunorubicin
  • Humans
  • Leukemia, Myeloid, Acute* / diagnosis
  • Leukemia, Myeloid, Acute* / epidemiology
  • Leukemia, Myeloid, Acute* / etiology
  • Myelodysplastic Syndromes* / diagnosis
  • Myelodysplastic Syndromes* / epidemiology
  • Myelodysplastic Syndromes* / etiology

Substances

  • CPX-351
  • Cytarabine
  • Daunorubicin